1. The Essentials for Secondary Stroke Prevention

2. Program Goals

3. Patient Case

4. Goals for Anticoagulation Therapy in AF

5. OAC Is More Effective Than Aspirin for Secondary Stroke Prevention in AF

6. RE-LY Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

7. ROCKET AF Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

8. ARISTOTLE Subgroup Analysis Time to Stroke or SE in Patients With/Without Previous Stroke or TIA

9. ENGAGE AF-TIMI 48 Subgroup Analysis Patient Characteristics

10. Outcomes With Edoxaban vs Warfarin in Patients With Previous Cerebrovascular Events

11. ICH Rate With Edoxaban vs Warfarin in Patients With Previous Cerebrovascular Events

12. Meta-Analysis in Secondary Stroke Prevention Stroke or SE

13. Meta-Analysis in Secondary Stroke Prevention Hemorrhagic Stroke

14. NOAC Meta-Analysis in Secondary Stroke Prevention: Conclusions

15. 2016 ESC Guidelines for the Management of AF

16. Initiation or Resumption of Anticoagulation Depends on Severity of Stroke*

17. ESC Guidelines Use of Aspirin for Secondary Stroke Prevention

18. Choosing a Particular OAC and Dose for Stroke Prevention in Individual Patients With NVAF

19. Summary

20. Abbreviations

21. Abbreviations (cont)

22. Abbreviations (cont)